What a Failed Heart Drug Reveals About an Entire Drug Class
A study with 1,432 patients, an established mechanism of action, a billion-dollar market — and then a result nobody expected. When AstraZeneca and Ionis Pharmaceuticals announced in July 2026 that their jointly developed drug Wainua (eplontersen) had missed the primary endpoint of a major Phase 3 trial, it was more than a failed indication expansion. It was an event that called an entire class of drugs — so-called silencer therapies — into question, while also illustrating how tightly trial design, competitive dynamics, and scientific interpretation are intertwined in oncology and cardiology alike.
What Exactly Went Wrong
Wainua is already used successfully to treat the rarer, nerve-predominant form of transthyretin amyloidosis. With the CARDIO-TTRansform trial, AstraZeneca and Ionis sought to make the drug available for the more common, heart-predominant form as well — transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive and often fatal disease in which misfolded protein accumulates in the heart muscle.
In the largest ATTR-CM trial to date, involving 1,432 participants, patients received either monthly eplontersen injections or placebo over 140 weeks, each on top of existing standard therapy. The result: 29 percent of the treatment group experienced a cardiovascular event or death, compared with 32 percent in the placebo group — a difference that was not statistically significant.
Why the Trial Design Itself Became the Story
A detail that analysts quickly identified as the central issue is especially revealing for understanding the case: 57 percent of trial participants were already taking a so-called stabilizer at baseline, such as Pfizer's Vyndaqel, which stabilizes misfolded proteins in the heart rather than reducing their production. Another 24 percent started taking a stabilizer during the trial. Wainua, however, works on a different principle: like Alnylam's Amvuttra, it reduces production of the misfolded protein directly at the source. Administering both mechanisms of action simultaneously made it harder to cleanly demonstrate Wainua's independent effect statistically.
This constellation ignited a fundamental debate: are oral stabilizers potentially superior to injectable silencer drugs in ATTR-CM? Several analysts read the trial result as evidence of exactly that — an interpretation that could have industry-wide consequences for the development of future RNA-based cardiac therapies.
The Market Reaction: One Competitor Fades, Two Others Benefit
Stock price reactions were significant. Ionis shares fell nearly 21 percent, and AstraZeneca also declined. At the same time, shares of Alnylam Pharmaceuticals and BridgeBio Pharma — both makers of competing ATTR-CM drugs — rose between 6 and 16 percent. The reason: with Wainua's failure, a potentially major competitor disappears from a fiercely contested market. Alnylam's Amvuttra alone generated $1.9 billion in revenue in the first half of 2026, accounting for 86 percent of the company's total revenue.
At a European Society of Cardiology congress in Munich, where the complete trial data were presented in late August 2026, market observers also raised a follow-up question: could Alnylam's own next-generation compound, nucresiran, meet a similar fate? Its pivotal trial likewise permits concurrent use of stabilizers — a trial-design detail that investors are watching closely in the wake of the Wainua setback.
What This Means for the Industry
For AstraZeneca, analysts believe the setback is less a question of company valuation than of scientific reputation. One Jefferies analyst put it pointedly: AstraZeneca is generally regarded as a company with an exceptionally strong track record in trial design — a failed endpoint in such a large-scale trial carries correspondingly heavy weight for the credibility of future development programs.
For the industry as a whole, the case offers a lesson in just how decisive the choice of comparator group and background therapies can be for the interpretability of clinical trials — particularly when multiple mechanisms of action compete for the same patients within an already small, specialized indication.
Sources
- BioPharma Dive, Jul 9, 2026 – AstraZeneca, Ionis drug fails big heart disease study in major setback
- BioPharma Dive, Aug 28, 2026 – AstraZeneca, Ionis data spark debate about RNA drugs' impact on deadly heart disease
- PharmExec – AstraZeneca Shares Drop Following Wainua's Failed Heart Disease Trial
- STAT News, Aug 27, 2026 – Alnylam's heart drug troubles take center stage at a cardiology conference
- STAT News, Aug 28, 2026 – AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
- STAT News, Aug 28, 2026 – In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
- Stocktwits, Aug 28, 2026 – IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial
- STAT News, Jul 9, 2026 – Pharmalittle: We're reading about FDA commissioner contenders, a heart drug failure, and more
Adrian Kempf
Pharma Communications Writer, Graphic & Media Designer Kirchzarten im Dreisamtal, Germany
Usage & Citation Permission
Full or partial reproduction of this text is permitted with source attribution. Please cite as:
"Adrian Kempf, pharmavisuell"
This text may be forwarded, published, shared on social media, or posted publicly.
Editorial abridgment is permitted as long as the meaning and message of the text are not distorted.
This usage permission applies to the specialist articles published on pharmavisuell.de. Individually commissioned texts are subject to separately agreed usage rights.
© Adrian Kempf, pharmavisuell – Kirchzarten im Dreisamtal
https://pharmavisuell.de